SCHEDULE 13G/A: BlackRock Amends Passive Stake in Sana Biotechnology, Holding 4.9% of Common Stock
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% of Sana Biotechnology, Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Sana Biotechnology, Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 11,027,189 shares of Sana Biotechnology, Inc. Common Stock.
- This ownership represents 4.9% of the total outstanding class of Sana Biotechnology, Inc. Common Stock.
- BlackRock holds sole voting power over 10,873,442 shares and sole dispositive power over 11,027,189 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Various BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that beneficially own shares, though no single entity owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing passive beneficial ownership. It contains factual information without any positive or negative implications for the company's operations or financial performance, thus indicating a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large institutional asset manager, BlackRock, Inc., indicating its passive investment stake in a biotechnology company, Sana Biotechnology, Inc. Such filings are common for large funds that hold diversified portfolios and cross certain ownership thresholds, reflecting standard portfolio management rather than a specific strategic move related to the biotechnology industry's trends.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires the filing of this statement (reporting period end). |
| 04/25/2025 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Sana Biotechnology, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.